In Vitro Modulation of Glibenclamide Transport by P-glycoprotein Inhibitory Antidiabetic African Plant Extracts^{[ 1 ]}

Abstract

The rise of diabetes incidence in Nigeria enhances the use of popular remedies that may interact with conventional therapies. The aqueous extracts of 27 popular Nigerian “antidiabetic” plants were tested for their in vitro effects on glutathione levels within HepG2 cells, P-glycoprotein (P-gp)-mediated Rh-123 efflux activity in Caco-2 vincristine-resistant cells, and modulation of glibenclamide transport in Caco-2 monolayers. The extract from Ximenia americana significantly depleted intracellular glutathione at 100 µg/mL similarly to the reference buthionine sulphoximine (p < 0.05). Other 10 extracts raised glutathione levels. Eight extracts inhibiting P-gp efflux in a concentration-dependent manner (p < 0.01) were selected for further evaluation in a bi-directional transport model across Caco-2 monolayers: Annona senegalensis, Bridellia ferruginea, Cassytha filiformis, Daniellia ogea, Khaya ivorensis, Syzygium guineense, Terminalia avicennioides, and X. americana. When interferences in paracellular transport were discarded, only 3 of them may be modulating the efflux ratio of glibenclamide (efflux ratio: 2.65 ± 0.13) in the same manner the reference drug verapamil (efflux ratio: 1.14 ± 0.25, p < 0.01) does: Syzygium guineense (efflux ratio: 1.70 ± 0.23, p < 0.01), Terminalia avicennioides (efflux ratio: 1.80 ± 0.25, p < 0.05), and X. americana (efflux ratio: 1.66 ± 0.10, p < 0.01). HPLC-UV analyses for P-gp inhibitors in these extracts revealed several phenolic compounds such as rutin, gallic acid, and ellagic acid reported to decrease P-gp expression and/or directly modify its function. In conclusion, some popular herbal medicines used by Nigerian diabetic patients are here shown to potentially affect glibenclamide absorption at concentrations that could be reached in the intestinal tract.

Key words

diabetes - drug interactions - P-glycoprotein - glyburide - glutathione - Syzygium guineense - Terminalia avicennioides - Ximenia Americana

• References

• 1 Campbell-Tofte J, Mølgaard P, Winther K. Harnessing the potential clinical use of medicinal plants as anti-diabetic agents. Bot Targets Ther 2012; 2: 7
• 2 May M, Schindler C. Clinically and pharmacologically relevant interactions of antidiabetic drugs. Ther Adv Endocrinol Metab 2016; 7: 69-83
• 3 Allen BL, Bush TM, Elizabeth R, Greyber MD, Holloway SW, Kantor S, Lam T, Rayburn KS, Roth LW, Sanchez-Yamamoto DS, So BK, De H, Tran M. Adverse interactions between herbal and dietary substances and prescription. Altern Ther Health Med 2007; 13: 30-35
• 4 Ezuruike UF, Prieto JM. The use of plants in the traditional management of diabetes in Nigeria: pharmacological and toxicological considerations. J Ethnopharmacol 2014; 155: 857-924
• 5 Ezuruike U, Prieto JM. Assessment of potential herb-drug interactions among Nigerian adults with type-2 diabetes. Front Pharmacol 2016; 7: 248
• 6 Zhang D, Luo G, Ding X, Lu C. Preclinical experimental models of drug metabolism and disposition in drug discovery and development. Acta Pharm Sin B 2012; 2: 549-561
• 7 Bogacz A, Deka-Pawlik D, Bartkowiak-Wieczorek J, Karasiewicz M, Kujawski R, Kowalska A, Chałas A, Czerny B, Grześkowiak E, Mrozikiewicz PM, Bogacz A, Deka-Pawlik D, Bartkowiak-Wieczorek J, Karasiewicz M, Kujawski R, Kowalska A, Chałas A, Czerny B, Grześkowiak E, Mrozikiewicz PM. The effect of herbal materials on the P-glycoprotein activity and function. Herba Pol 2013; 59: 129-141
• 8 Gedeon C, Behravan J, Koren G, Piquette-Miller M. Transport of glyburide by placental abc transporters: implications in fetal drug exposure. Placenta 2006; 27: 1096-1102
• 9 Golstein PE, Boom A, van Geffel J, Jacobs P, Masereel B, Beauwens R. P-glycoprotein inhibition by glibenclamide and related compounds. Pflugers Arch 1999; 437: 652-660
• 10 Lilja JJ, Niemi M, Fredrikson H, Neuvonen PJ. Effects of clarithromycin and grapefruit juice on the pharmacokinetics of glibenclamide. Br J Clin Pharmacol 2007; 63: 732-740
• 11 Jover R, Bort R, Gómez-Lechón MJ, Castell JV. Re-expression of C/EBPα induces CYP2B6, CYP2C9 and CYP2D6 genes in HepG2 cells. FEBS Lett 1998; 431: 227-230
• 12 Huang ZZ, Chen C, Zeng Z, Yang H, Oh J, Chen L, Lu SC. Mechanism and significance of increased glutathione level in human hepatocellular carcinoma and liver regeneration. FASEB J 2001; 15: 19-21
• 13 Forster S, Thumser AE, Hood SR, Plant N. Characterization of rhodamine-123 as a tracer dye for use in in vitro drug transport assays. PLoS One 2012; 7: e33253
• 14 Chieli E, Romiti N, Rodeiro I, Garrido G. In vitro effects of Mangifera indica and polyphenols derived on ABCB1/P-glycoprotein activity. Food Chem Toxicol 2009; 47: 2703-2710
• 15 Chieli E, Romiti N, Rodeiro I, Garrido G. In vitro modulation of ABCB1/P-glycoprotein expression by polyphenols from Mangifera indica . Chem Biol Interact 2010; 186: 287-294
• 16 Kitagawa S, Nabekura T, Kamiyama S, Takahashi T, Nakamura Y, Kashiwada Y, Ikeshiro Y. Effects of alkyl gallates on P-glycoprotein function. Biochem Pharmacol 2005; 70: 1262-1266
• 17 Zhang HM, Zhao L, Li H, Xu H, Chen WW, Tao L. Research progress on the anticarcinogenic actions and mechanisms of ellagic acid. Cancer Biol Med 2014; 11: 92-100
• 18 Tan KW, Li Y, Paxton JW, Birch NP, Scheepens A. Identification of novel dietary phytochemicals inhibiting the efflux transporter breast cancer resistance protein (BCRP/ABCG2). Food Chem 2013; 138: 2267-2274
• 19 Mohana S, Ganesan M, Agilan B, Karthikeyan R, Srithar G, Beaulah Mary R, Ananthakrishnan D, Velmurugan D, Rajendra Prasad N, Ambudkar SV. Screening dietary flavonoids for the reversal of P-glycoprotein-mediated multidrug resistance in cancer. Mol Biosyst 2016; 12: 2458-2470
• 20 Hilgers AR, Conradi RA, Burton PS. Caco-2 cell monolayers as a model for drug transport across the intestinal mucosa. Pharm Res 1990; 07: 902-910
• 21 Ranaldi G, Consalvo R, Sambuy Y, Scarino ML. Permeability characteristics of parental and clonal human intestinal Caco-2 cell lines differentiated in serum-supplemented and serum-free media. Toxicol In Vitro 2003; 17: 761-767
• 22 Balimane PV, Han YH, Chong S. Current industrial practices of assessing permeability and P-glycoprotein interaction. AAPS J 2006; 8: E1-E13
• 23 Narai A, Arai S, Shimizu M. Rapid decrease in transepithelial electrical resistance of human intestinal Caco-2 cell monolayers by cytotoxic membrane perturbents. Toxicol In Vitro 1997; 11: 347-354
• 24 Renes J, de Vries EG, Nienhuis EF, Jansen PL, Müller M. ATP- and glutathione-dependent transport of chemotherapeutic drugs by the multidrug resistance protein MRP1. Br J Pharmacol 1999; 126: 681-688
• 25 Cole SPC, Deeley RG. Transport of glutathione and glutathione conjugates by MRP1. Trends Pharmacol Sci 2006; 27: 438-446
• 26 Ballatori N, Krance SM, Marchan R, Hammond CL. Plasma membrane glutathione transporters and their roles in cell physiology and pathophysiology. Mol Aspects Med 2009; 30: 13-28
• 27 Giner RM, Recio MC, Cuellar MJ, Máñez S, Peris JB, Stobing G, Mateu I, Rios JL. A taxonomical study of the subtribe Leontodontinae based on the distribution of phenolic compounds. Biochem Syst Ecol 1993; 21: 613-616
• 28 Repetto G, del Peso A, Zurita JL. Neutral red uptake assay for the estimation of cell viability/cytotoxicity. Nat Protoc 2008; 3: 1125-1131
• 29 Allen S, Shea JM, Felmet T, Gadra J, Dehn PF. A kinetic microassay for glutathione in cells plated on 96-well microtiter plates. Methods Cell Sci 2000; 22: 305-312
• 30 Rahman I, Kode A, Biswas SK. Assay for quantitative determination of glutathione and glutathione disulfide levels using enzymatic recycling method. Nat Protoc 2006; 1: 3159-3165
• 31 Hubatsch I, Ragnarsson EGE, Artursson P. Determination of drug permeability and prediction of drug absorption in Caco-2 monolayers. Nat Protoc 2007; 2: 2111-2119